Physician profile
Nancy Eisele
NPI 1952318370
$3,540.30
in general payments reported to CMS, 2019-2025
27 companies · $350 in 2025
The $350 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $1,281 · 2021: $259 · 2022: $680 · 2023: $383 · 2024: $279 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,149.72 | 2020 | |
| Alcon Vision LLC | $601.13 | 2020-2025 | Hydrus Microstent, Centurion, Clareon |
| New World Medical,INC. | $488.25 | 2021-2022 | |
| Abbvie INC. | $272.48 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $157.85 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $132.57 | 2019-2021 | |
| Allergan, INC. | $82.80 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $81.58 | 2019-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $76.57 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $44.35 | 2023-2024 | Xiidra, Stellaris |
| Kala Pharmaceuticals, INC. | $39.67 | 2019 | |
| Rxsight INC | $35.83 | 2022 | |
| Shire North American Group INC | $35.63 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $35.22 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.04 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $31.93 | 2022 | |
| Leadiant Biosciences, INC. | $30.05 | 2024 | Carnitor |
| Amgen INC. | $28.16 | 2025 | Tepezza |
| Harrow Eye, LLC | $28.06 | 2024 | Iheezo |
| Oyster Point Pharma, INC. | $26.16 | 2025 | Tyrvaya, Ryzumvi |
| Thea Pharma INC. | $22.87 | 2023 | Iyuzeh |
| Dompe US, INC. | $22.25 | 2025 | Oxervate |
| Biotissue Holdings INC. | $21.65 | 2024 | |
| Rayner Intraocular Lenses Limited | $19.04 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $17.29 | 2022 | |
| Omeros Corporation | $14.56 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Eisele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.